Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financi...((R) : For the quarter ended December 3...),Health

Date:2/27/2009

(R): For the quarter ended December 31, 2008, net sales of LIDODERM decreased 2% to $205.4 million compared with $208.7 million in the same period a year ago. Prescription volume for LIDODERM increased 1% in the fourth quarter of 2008 versus the comparable 2007 period. For the year ended December 31, 2008, net sales of LIDODERM increased 8% to $765.1 million compared with $705.6 million in the same period a year ago. Prescription volume for LIDODERM increased 6% in the twelve months of 2008 versus the comparable 2007 period.

OPANA(R) ER and OPANA(R): Combined net sales for the OPANA franchise increased 81% to $52.3 million for the fourth quarter 2008 compared with $28.9 million in the same period a year ago. Prescription volume for OPANA ER and OPANA increased 64% in the fourth quarter 2008 versus the comparable 2007 period. For the year ended December 31, 2008, net sales for the OPANA franchise increased 68% to $180.4 million compared with $107.1 million in the same period a year ago. The 2007 annual results include the recognition of $13.8 million in deferred revenue for commercial shipments of OPANA ER and OPANA made to customers in 2006.

PERCOCET(R): Net sales of PERCOCET were $33.4 million for the three months ended December 31, 2008 compared with $30.6 million in the same period in 2007. Net sales of PERCOCET were $130.0 million for the year ended December 31, 2008 compared with $121.7 million in the same period in 2007.

FROVA(R): Net sales of FROVA were $16.8 million for the three months ended December 31, 2008 compared with $14.1 million for the same period in 2007. Prescription volume increased 9% for the twelve months of 2008 versus the comparable 2007 period. For the year ended December 31, 2008, net sales of FROVA were $58.0 million compared with $52.4 million in the same period in 2007.

VOLTA
'/>"/>

SOURCE Endo Pharmaceuticals Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine news :

1. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
2. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
3. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
4. Endo Pharmaceuticals Appoints William Montague to Board of Directors
5. Access Pharmaceuticals Closes Acquisition of MacroChem Corp.
6. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
7. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
8. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
9. Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
10. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
11. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results